Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.47 |
| ▸ | POLB | P06746 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12040651 | 0.92 | POLB (0.44) | F10POLBMAPTGRM1TP53 | |
| SCHEMBL8230285 | 0.90 | F10 (0.41) | F10POLBMAPTGRM1TP53 | |
| SCHEMBL3377544 | 0.86 | F10 (0.51) | F10POLBMAPTTP53TDP1 | |
| SCHEMBL3380128 | 0.85 | F10 (0.54) | F10GRM1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL3381165 | 0.85 | POLB (0.40) | F10POLBMAPTGRM1TP53 | |
| SCHEMBL3377538 | 0.81 | AHR (0.45) | F10GRM1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL3379941 | 0.81 | F10 (0.53) | F10POLBMAPTTP53TDP1 | |
| SCHEMBL13550371 | 0.80 | F10 (0.45) | F10POLBMAPTGRM1SMN1; SMN2 | |
| SCHEMBL3985616 | 0.79 | F10 (0.61) | F10 | |
| SCHEMBL13273193 | 0.79 | POLB (0.40) | F10POLBMAPTGRM1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029586-B1 | ISOINDOLIN-1-ONE-, ISOINDOLIN-3-ONE- AND ISOINDOLIN-1,3-DIONE-DERIVATIVES AND USE THEREOF | BAYER SCHERING PHARMA AG (DE) | 2010-11-24 | — | — | EP | disclosed |
| WO-2010077686-A1 | ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100010060-A1 | Isoindolin-1-One-, Isoindolin-3-One- and Isoindolin-1,3-Dione-Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2010-01-14 | — | — | US | disclosed |
| US-20100010060-A1 | Isoindolin-1-One-, Isoindolin-3-One- and Isoindolin-1,3-Dione-Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2010-01-14 | — | — | US | disclosed |
| US-20100010060-A1 | Isoindolin-1-One-, Isoindolin-3-One- and Isoindolin-1,3-Dione-Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2010-01-14 | — | — | US | disclosed |
| EP-2029586-A1 | ISOINDOLIN-1-ONE-, ISOINDOLIN-3-ONE- AND ISOINDOLIN-1,3-DIONE-DERIVATIVES AND USE THEREOF | Bayer HealthCare AG (DE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007137800-A1 | ISOINDOLIN-1-ONE-, ISOINDOLIN-3-ONE- AND ISOINDOLIN-1,3-DIONE-DERIVATIVES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010060-A1 | Isoindolin-1-One-, Isoindolin-3-One- and Isoindolin-1,3-Dione-Derivatives and Use Thereof | ICAM1, SERPINC1, TFPI2 | F10 264/4885POLB 2870/4885MAPT 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.